Top NYC, NY Telehealth Companies With Best Stability & Growth (59)

Profitability: Profitability is described as sustained since 2023 while the company continues to scale, pointing to durable unit economics. Company updates also indicate cash‑flow positivity and that efficiency targets such as the Rule of 40 have been surpassed.

Strong Revenue Growth: Revenue growth is characterized as strong over multiple years with momentum continuing into 2026. Acceleration is described alongside expansion in provider supply and booking channels.

Strategic Partnerships: New distribution and integrations, including embedded real‑time booking on Yelp and a payer partnership, broaden patient access points and reinforce growth. These partnerships extend reach beyond the core site into high‑traffic consumer and member channels.

Strong Hiring & Retention: Active recruiting is evident with 20+ open roles on Indeed across multiple states and functions, alongside a LinkedIn size band of 51–200 and recent activity signaling team buildout. Role postings span therapists, a remote RN health advocate, and operations/partnerships positions, indicating capacity expansion.

Market Expansion: Medicare-covered virtual therapy is marketed across all 50 states with state-by-state pages and booking via channels like Zocdoc, pointing to an enlarging go-to-market footprint. Site and blog updates through 2025–2026 and a market-launch role (e.g., Philadelphia) further support ongoing geographic growth.

Strategic Partnerships: A publicly announced collaboration with Advanced Nursing & Home Care and recent LinkedIn partnership/event posts suggest growing referral networks. These signals align with efforts to embed within senior-care ecosystems to broaden distribution.

Investor Backing & Capital Strength: Recent late-stage financings — a February 2026 Series D followed by a May 2026 Series E at a higher stated valuation — indicate strong capital access and confidence. Disclosures cite prominent investors and a sizable valuation step‑up, providing resources to scale.

Market Expansion: Company communications describe reach to almost 800 employer clients and multi‑million member coverage, signaling a broader commercial footprint across the employer market. New feature releases such as Predictive Outreach and added distribution channels support this expanding reach.

Strategic Partnerships: Collaborations announced in 2026 with Priority Health and Atlantic Health extend distribution to commercial employer groups through plan and health‑system channels. These partnerships reinforce access to steer members toward higher‑performing providers.

Investor Backing & Capital Strength: Capital raised includes a $35M Series A (2024), $70M Series B (2025), and $100M Series C (2026), with reports of a roughly $1.75B valuation. Consistent step-ups in round size and total funding signal traction and confidence to fuel scale.

Profitability: Profitability is reported for 2025, unusual among digital health peers at this stage. This indicates operating leverage with payer reimbursement working as intended.

Strategic Partnerships: Payer coverage spans national commercial plans plus Medicare and Medicaid, a key lever for patient acquisition and revenue consistency in virtual care. Broad distribution is reflected in nationwide availability and hundreds of thousands of patients served.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list in 2024 and 2025 indicates multi‑year revenue expansion. This sustained recognition points to continued top‑line momentum through mid‑2026.

Innovation-Driven Growth: Recent AI launches for ABA operations (e.g., an AI dashboard and AI‑assisted documentation) reflect active product investment. This cadence suggests a focus on differentiation and upsell potential across the platform.

Market Expansion: Expansion via acquisition—most notably the August 2025 purchase of Joshin—positions the portfolio to cover broader neurodiversity and disability support. Partnerships and integrations alongside broad employer, education, and provider adoption indicate a scaling footprint.

Investor Backing & Capital Strength: Multiple late‑stage rounds since 2024, including a $72M Series C in 2025 and a reported $162M total raised, indicate robust external support and runway.

Strategic Partnerships: Named deals in 2026 with Zurich (UK), Transamerica, and Equitable, alongside claims of working with 8 of the top 10 U.S. life insurers, broaden access to millions of beneficiaries. Zurich UK provides independent confirmation of rollout.

Market Expansion: Geographic availability has widened from the U.S. into Canada and the U.K., supported by insurer and bank launches in 2025–2026. This expansion increases potential reach across North America and Europe.

Investor Backing & Capital Strength: Recent financing includes a June 2024 seed and an October 2025 $15.5M Series A led by Costanoa with Town Hall Ventures and Khosla, positioned to fund hiring, product, and market expansion. Public investor and media materials describe this capital as intended to scale operations and partnerships.

Market Expansion: Operations are described as growing beyond New York into New Jersey and Ohio, with compliance entities in multiple states and localized, multilingual school pages signaling multi‑district deployment. District approvals and company updates point to a widening on‑the‑ground footprint.

Strategic Partnerships: Public district materials (e.g., Millville Public Schools and Upper Deerfield Township in NJ) announce Marble programs, indicating active school partnerships. Company communications highlight a school‑centered model built specifically for schools, reinforcing this partnership‑led growth.

Investor Backing & Capital Strength: Back-to-back raises—a $32M Series A (2024) and a $50M Series B (2025)—are noted as fuel to hire, build, and scale. The Series B was led by Key1 Capital with participation from existing investors, signaling strong capital support.

Product Line Growth: New offerings such as “Zoe for HR” launched on June 11, 2026, along with AI-powered claims analytics and other enhancements, indicate continued investment and iteration. These additions expand functionality beyond core navigation into analytics and cost containment.

Strategic Partnerships: Collaborations and channels including TriNet, PrismHR, and joining the Workday Wellness Program extend distribution into employer and PEO ecosystems. Additional relationships (e.g., Homethrive) broaden the platform’s scope and access.

Strong Revenue Growth: Independent analysis indicates revenue reaccelerated in 2024 with GLP‑1 weight‑management becoming the primary engine. Signals since late 2023 point to material momentum tied to the Ro Body program.

Strategic Partnerships: Integrations with Eli Lilly (LillyDirect Zepbound vials) and Novo Nordisk (Wegovy pill launch and multi‑month subscription program) broaden branded access and price positioning on Ro’s platform. These manufacturer ties are presented as key levers for authentic supply and scaled distribution.

Market Expansion: Participation in the nationwide launch of the Wegovy pill and development of insurance‑navigation tools expand the GLP‑1 channel and lower access frictions. Movement into employer and health‑plan pathways aims to extend reach beyond purely cash‑pay dynamics.

Investor Backing & Capital Strength: Capital access is described as exceptional, with over $1B in total funding and a valuation rising to $5.3B across successive rounds backed by top‑tier and strategic investors. This depth of financing signals ample runway for R&D and go‑to‑market scale.

Strong Revenue Growth: Revenue momentum is highlighted by contracted ARR of $117M in early 2025 and estimates that actual ARR crossed $100M by mid‑2025, alongside a 4x increase over 18 months. These points indicate rapid monetization of enterprise deployments.

Market Expansion: Enterprise adoption expanded from roughly 100–150 health systems in early/mid‑2025 to more than 250–300 by mid‑2026, including large rollouts at Kaiser Permanente and other marquee systems. Scaling conversation volume from ~50M in 2025 to a projected 80M+ in 2026 underscores a widening footprint.

Strong Market Position & Advantage: Evidence indicates USPI leads the ambulatory surgery center sector by footprint and market standing, consistently referenced as the largest national platform. Industry and company descriptions highlight broad scale, procedure volume, and leadership within a consolidating yet fragmented market.

Strong Revenue Growth: Descriptions point to steady year-over-year increases in ambulatory segment revenue and earnings through 2024–2025, with raised outlooks signaling sustained momentum. Same-facility growth and higher revenue per case underscore a durable top-line trajectory.

Market Expansion: Evidence shows rapid network growth via acquisitions and de novo centers across many states and specialties. Partnerships and joint ventures with physician groups and health systems further extend geographic reach and service breadth.

Strategic Partnerships: CVS Health’s acquisition and integration, including co-located clinics and access to CVS and Aetna channels, provide scale and distribution advantages. The exclusive AARP partnership strengthens credibility and reach among Medicare seniors.

Market Expansion: Continuous opening of new centers across additional states and in-store formats signals sustained geographic growth. Hiring momentum and plans to surpass prior center counts indicate ongoing expansion capacity.

Strong Market Position & Advantage: Positioning as a leader in value-based primary care for older adults is reinforced by distinctive outcomes-focused care and technology enablement. Focus on underserved communities further differentiates the model from traditional peers.

Market Expansion: Operations span 36 states with accelerating cumulative session volumes, indicating broadening geographic reach and utilization. Reported throughput has grown from hundreds of thousands to well over half a million total sessions since launch.

Product Line Growth: Offerings extend beyond sublingual ketamine to include at‑home injectables, alongside new programs (e.g., PTSD focus), group integration circles, and a mobile app. This broadening portfolio signals continued product innovation and capability building.

Strong Market Position & Advantage: The company is frequently identified as a leading at‑home ketamine provider by volume, outcomes publications, and brand visibility within its niche. Structured clinician guidance, coaching, and integration support differentiate it from lower‑touch or lower‑cost alternatives.